Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
LEXINGTON, Mass and AMSTERDAM, the Netherlands, Aug. 24, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in a gene therapy panel discussion and host investor meetings during the Citi Healthcare Conference held in Boston from September 5-7, 2017.
Matt Kapusta, chief executive officer of uniQure, will participate on the analyst-moderated panel entitled, “Gene-Therapy Manufacturing and Regulatory – Challenges and Opportunities” on Thursday, September 7, 2017 at 11:00 am EDT. A live webcast of the panel discussion can be accessed through the link displayed in the Investor Section of the uniQure website at http://uniqure.com/investors-newsroom/events-presentations.php. A replay of the webcast will be available within 24 hours following the event, and will remain available for at least two weeks.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com
uniQure Contacts: For Investors: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 [email protected] Eva M. Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 [email protected] For Media: Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 [email protected]
